Tumors of female reproductive systemTumors of female reproductive systemОпухоли женской репродуктивной системы1994-40981999-8627Publishing House ABV Press3610.17650/1994-4098-2013-0-1-2-23-27MAMMOLOGY. TREATMENTМАММОЛОГИЯ. ЛЕЧЕНИЕTime course of changes in bone resorption markers during pamidronate therapy in breast cancer patients with bone metastasesДинамика маркеров костной резорбции на фоне терапии памидронатом больных раком молочной железы с костными метастазамиPetrovaA. D.ПетроваА. Д.
Russian Federation
dr.apetrova@gmail.comSteninaM. B.СтенинаМ. Б.
Russian Federation
ManzyukL. V.МанзюкЛ. В.
Russian Federation
LyubimovaN. V.ЛюбимоваН. В.
Russian Federation
TyulyandinS. A.ТюляндинС. А.
Russian Federation
N.N. Blokhin Russian Cancer Research Center, Russian Academy of Medical Sciences, MoscowФГБУ «РОНЦ им. Н.Н. Блохина» РАМН, Москва210520131-2232721072014210720142013https://ojrs.abvpress.ru/ojrs/article/view/36

The paper gives the results of evaluating the time course of changes in the level of bone resorption markers (S-CTx and dPir) in pami- dronate-treated patients with bone metastases from breast cancer. It shows the relationship of these markers to clinical and X-ray find- ings. The markers were not found to be of high clinical significance as a means for diagnosing bone metastases and estimating treat- ment trends.

Приведены результаты оценки динамики уровня маркеров костной резорбции (S-CTx и дПир) у больных с костными метастаза- ми рака молочной железы, получавших памидронат. Показана взаимосвязь этих маркеров с данными клинико-рентгенологической картины. Не выявлено высокой клинической значимости маркеров в качестве средства диагностики костных метастазов и оцен- ки динамики лечения.

breast cancerbone metastasesbone resorption markersрак молочной железыкостные метастазымаркеры костной резорбции1. Delmas P.D., Schlemmer A., Gineyts E. et al. Urinary excretion of pyridinoline crosslinks correlates with bone turnover measured on iliac crest biopsy in patients with vertebral osteoporosis. J Bone Miner Res 1991;6(6):639–44.Delmas P.D., Schlemmer A., Gineyts E. et al. Urinary excretion of pyridinoline crosslinks correlates with bone turnover measured on iliac crest biopsy in patients with vertebral osteoporosis. J Bone Miner Res 1991;6(6):639–44.2. Eyre D.R., Dickson I.R., Van Ness K.P. Collagen cross-linking in human bone and articular cartilage. Age-related changes in the content of mature hydroxypyridinium residues. Biochem J 1988;252(2):495–500.Eyre D.R., Dickson I.R., Van Ness K.P. Collagen cross-linking in human bone and articular cartilage. Age-related changes in the content of mature hydroxypyridinium residues. Biochem J 1988;252(2):495–500.3. Knott L., Bailey A.J. Collagen cross-links in mineralizing tissues: a review of their chemistry, function, and clinical relevance. Bone 1998;22(3):181–7.Knott L., Bailey A.J. Collagen cross-links in mineralizing tissues: a review of their chemistry, function, and clinical relevance. Bone 1998;22(3):181–7.4. Seibel M.J., Woitge H., Scheidt-Nave C. et al. Urinary hydroxypyridinium cross links of collagen in population-based screening for overt vertebral osteoporosis: results of a pilot study. J Bone Miner Res 1994;9(9):1433–40.Seibel M.J., Woitge H., Scheidt-Nave C. et al. Urinary hydroxypyridinium cross links of collagen in population-based screening for overt vertebral osteoporosis: results of a pilot study. J Bone Miner Res 1994;9(9):1433–40.5. Woitge H.W., Pecherstorfer M., Li Y. et al. Novel serum markers of bone resorption: clinical assessment and comparison with established urinary indices. J Bone Miner Res 1999;14(5):792–801.Woitge H.W., Pecherstorfer M., Li Y. et al. Novel serum markers of bone resorption: clinical assessment and comparison with established urinary indices. J Bone Miner Res 1999;14(5):792–801.6. Seibel M.J., Gartenberg F., Silverberg S.J. et al. Urinary hydroxypyridinium cross-links of collagen in primary hyperparathyroidism. J Clin Endocrinol Metab 1992;74(3):481–6.Seibel M.J., Gartenberg F., Silverberg S.J. et al. Urinary hydroxypyridinium cross-links of collagen in primary hyperparathyroidism. J Clin Endocrinol Metab 1992;74(3):481–6.7. Lipton A., Costa L., Coleman R.E. Bone turnover markers: tools for prognoses and monitoring response to bisphosphonates? Breast Dis 2011;33(2):59–69.Lipton A., Costa L., Coleman R.E. Bone turnover markers: tools for prognoses and monitoring response to bisphosphonates? Breast Dis 2011;33(2):59–69.8. Coleman R.E., Costa L., Saad F. et al. Consensus on the utility of bone markers in the malignant bone disease setting. Crit Rev Oncol Hematol 2011;80(3):411–32.Coleman R.E., Costa L., Saad F. et al. Consensus on the utility of bone markers in the malignant bone disease setting. Crit Rev Oncol Hematol 2011;80(3):411–32.9. Coleman R.E., Brown J., Terpos E. et al. Bone markers and their prognostic value in metastatic bone disease: clinical evidence and future directions. Cancer Treat Rev 2008;34(7):629–39.Coleman R.E., Brown J., Terpos E. et al. Bone markers and their prognostic value in metastatic bone disease: clinical evidence and future directions. Cancer Treat Rev 2008;34(7):629–39.10. Lipton A., Chapman J.W., Demers L. et al. Use of elevated bone turnover to predict bone metastasis. J Clin Oncol 2008;26(Suppl):28s [abstr 591].Lipton A., Chapman J.W., Demers L. et al. Use of elevated bone turnover to predict bone metastasis. J Clin Oncol 2008;26(Suppl):28s [abstr 591].11. Hou M.F., Tsai L.Y., Tsai S.M. et al. Biochemical markers for assessment of bone metastases in patients with breast cancer. Kaohsiung J Med Sci 1999;15(8):452–60.Hou M.F., Tsai L.Y., Tsai S.M. et al. Biochemical markers for assessment of bone metastases in patients with breast cancer. Kaohsiung J Med Sci 1999;15(8):452–60.